Biden’s Pharma Partnership With $5 Billion Funding Draws Scam Allegations


According to Reuters:

The U.S. government is spending over $5 billion on an effort to speed up the development of new COVID-19 vaccines and treatments, a Department of Health and Human Services (HHS) spokesperson and a Biden administration official said on Monday.

In an interview with the Washington Post, the White House and HHS officials first announced the investment as “Project NextGen”. It is designed to provide better protection against coronaviruses, including the one that causes COVID-19 and could be a future threat.

This clever nicknaming of government agendas is a little unusual, just as an aside. Can semantical engineering such as this be used to infantilize people by giving catchy titles for nefarious government projects to soothe suspicion?

President Joe Biden’s administration will spend at most $5 billion on partnerships with the private sector. This approach is very similar to that used by “Operation Warp Speed,” a project of former President Donald Trump. It accelerated the development and distribution of vaccines in 2020.

These are not collaborations with the private sector. These are large-scale transfers of public money to the private sector. This is the gifting of pharmaceutical companies (who then pay it back to politicians, bureaucrats, and their back ends) with billions in taxpayer money to create new products. They don’t pay any tax back and actually price-gouge taxpayers.

This fascism is true, and in the sense, Benito Mussolini intended: “merger corporation and state power”.


To stimulate scientific progress in areas of high public-health benefit to Americans, it will take at least $5 billion. This investment will also contribute to the development of effective and safe tools for American citizens.

A spokesperson for HHS said that the project would be located at HHS. It will collaborate with the government as well as the private sector to create a pipeline of vaccines. This project will cover all stages of development from clinical trials to delivery.

It’s not necessary to create new medical products. The subsidy isn’t needed for one of the most profitable industries in history.